成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 656247-17-5 Chemical Structure| 656247-17-5
Chemical Structure| 656247-17-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 656247-17-5

,{[proInfo.pro_purity]}

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3, and PDGFRα/β with IC50 values of 34 nM, 13 nM, 13 nM, 69 nM, 37 nM, 108 nM, 59 nM, and 65 nM, respectively.

Synonyms: BIBF 1120; Intedanib

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Nintedanib

CAS No. :656247-17-5
Formula : C31H33N5O4
M.W : 539.62
SMILES Code : O=C(C1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(N(C)C(CN4CCN(C)CC4)=O)C=C3)/C5=CC=CC=C5)OC
Synonyms :
BIBF 1120; Intedanib
MDL No. :MFCD11974012
InChI Key :CPMDPSXJELVGJG-UHFFFAOYSA-N
Pubchem ID :135423438

Safety of Nintedanib

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301-H315-H318-H361-H372
Precautionary Statements:P201-P202-P260-P264-P270-P280-P301+P310+P330-P302+P352-P305+P351+P338+P310-P308+P313-P332+P313-P405-P501
Class:6.1
UN#:2811
Packing Group:Ⅲ

Isoform Comparison

Biological Activity

Target

  • VEGFR1

    VEGFR1, IC50:34 nM

  • VEGFR3

    VEGFR3, IC50:13 nM

  • VEGFR2

    VEGFR2, IC50:13 nM

  • PDGFRβ

    PDGFRβ, IC50:65 nM

In Vitro:

Cell Line
Concentration Treated Time Description Reference
B16-F10 cells 1 μM 72 h To evaluate the effect of Nintedanib on the viability of B16-F10 cells, results showed that Nintedanib did not attenuate the viability of B16-F10 cells at concentrations up to 1 μM. PMC7921555
NIH-3T3 cells 0.5 or 1 μM 72 h To evaluate the effect of Nintedanib on the viability and proliferation of NIH-3T3 cells, results showed that Nintedanib attenuated the viability and proliferation of NIH-3T3 cells stimulated with TGF-β1. PMC7921555
HCT116 IGF2BP2 KO cells 8.2 μM 96 h To evaluate the growth inhibitory effect of Nintedanib on HCT116 IGF2BP2 KO cells. Results showed that Nintedanib significantly inhibited the growth of HCT116 IGF2BP2 KO cells in 3D cell culture. PMC10227963
MKN-45 100 nM and 10 μM 72 h SN-38 inhibited MKN-45 cell proliferation by 43.3% and 83.4% PMC9377761
KATO-III 100 nM and 10 μM 72 h SN-38 inhibited KATO-III cell proliferation by 31.7% and 65.6% PMC9377761
SNU-5 100 nM and 10 μM 72 h SN-38 inhibited SNU-5 cell proliferation by 51.1% and 84.8% PMC9377761
THP-1 human monocytic cells 0.01 μM, 0.10 μM, 1.00 μM 2.5 h Nintedanib significantly reduced the migration of THP-1 cells in response to CCL2 stimulation, and this effect was not through direct CCR2 antagonism. PMC11582469

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
C57BL/6J mice Chemically-induced fibrosis and tumor model Oral 50 mg/kg Weekly dosing until the end of the experiment Nintedanib significantly reduced the incidence of liver fibrosis and tumors, decreased tumor number and size, and did not cause significant weight loss or hepatotoxicity. PMC6815707
Mice Pulmonary fibrosis model Oral 60 mg/kg Once daily for 10 days To evaluate the therapeutic effect of Nintedanib on pulmonary fibrosis, results showed significant reduction in fibrosis PMC5760280
C57BL/6 mice B16-F10 tumour model Oral 50 mg/kg Five times a week for 2 weeks To evaluate the effect of Nintedanib on the B16-F10 tumour model, results showed that Nintedanib significantly delayed tumour growth and prolonged the survival of the mice. PMC7921555
Mice F420, K7M2, and OS-17 tumor models Oral 50 mg/kg Twice daily for 14 days Nintedanib prevented metastatic progression in multiple murine and human xenograft models by inhibiting osteosarcoma-induced fibrosis. PMC11739783
C57BL/6 mice Bleomycin-induced lung fibrosis model Intraperitoneal injection 30 mg/kg Once daily for 13 days To evaluate the anti-fibrotic effect of Nintedanib in a bleomycin-induced lung fibrosis model. PMC8249783
NOD/SCID mice peritoneal dissemination model intraperitoneal injection 25 mg/kg 5 times per week for 15 days Nintedanib monotherapy significantly extended animal survival (27 days, a 50% increase, P=0.0004), and further extended survival when combined with nal-IRI or IRI PMC9377761
Mice Bleomycin-induced lung fibrosis model Oral 60 mg/kg Daily for 14 days Nintedanib significantly reduced the number of CCR2+ cells in the lung and attenuated fibrosis. PMC11582469

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03361319 NSCLC, Recurrent ... More >> Adenocarcinoma of Lung Less << Phase 1 Phase 2 Not yet recruiting January 2022 -
NCT02863055 Malignant Pleural Mesothelioma Phase 2 Recruiting October 2020 Belgium ... More >> UZ Antwerpen Recruiting Antwerpen, Belgium Contact: Jan Van Meerbeeck, prof ?? ?? ?? UZ Gent Recruiting Gent, Belgium Contact: Veerle Surmont, Prof ?? ?? ?? Italy Ospedale San Paolo Recruiting Milan, Italy Contact: Andrea Luciani, Dr ?? ?? ?? United Kingdom Manchester University NHS Foundation Trust - UHSM-Wythenshawe Hospital Recruiting Wythenshawe, Manchester, United Kingdom, M23 9LT Principal Investigator: Paul Taylor ?? ?? ?? Royal Marsden Hospital Recruiting Chelsea, United Kingdom Contact: Sanjay Popat, Dr ?? ?? ?? Royal Marsden Hospital - Kingston Recruiting Kingston, United Kingdom Contact: Sanjay Popat, Dr ?? ?? ?? Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital Recruiting Sheffield, United Kingdom Contact: Robin Young, Dr ?? ?? ?? NHS South Tyneside-South Tyneside District Hospital Recruiting South Shields, United Kingdom Contact: Rhona McMenemin, Dr ?? ?? ?? Royal Marsden Hospital Recruiting Sutton, United Kingdom Contact: Sanjay Popat, Dr Less <<
NCT02597933 Scleroderma, Systemic Phase 3 Completed - -
NCT01770392 - Completed - -
NCT02607722 - Active, not recruiting January 31, 2020 Japan ... More >> Multiple Locations, Japan Less <<
NCT01770392 Healthy Phase 1 Completed - Germany ... More >> 1199.162.1 Boehringer Ingelheim Investigational Site Biberach, Germany Less <<
NCT02856425 Patients With Any Advanced Sol... More >>id Tumors Less << Phase 1 Suspended(Safety event) July 2026 France ... More >> Gustave Roussy Villejuif, Val De Marne, France, 94805 Less <<
NCT03710824 - Not yet recruiting January 13, 2021 -
NCT02452463 Radiation-Induced Pneumonitis ... More >> Stage IIA Non-Small Cell Lung Carcinoma Stage IIB Non-Small Cell Lung Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer Less << Phase 2 Recruiting January 7, 2020 United States, New York ... More >> Roswell Park Cancer Institute Recruiting Buffalo, New York, United States, 14263 Contact: Grace Dy ?? 716-845-3099 ?? Grace.Dy@RoswellPark.org ?? Principal Investigator: Grace Dy ?? ?? ?? United States, West Virginia West Virginia University Recruiting Morgantown, West Virginia, United States, 26506 Contact: Carloa Ross ?? 304-581-1158 ?? cjross@hsc.wvu.edu ?? Principal Investigator: Malcom Mattes, MD Less <<
NCT03287947 Appendix Cancer Phase 2 Recruiting March 1, 2022 United States, North Carolina ... More >> Levine Cancer Institute Recruiting Charlotte, North Carolina, United States, 28204 Contact: Nathan Thompson, RN ?? 980-487-3241 ?? Nathan.Thompson@carolinashealthcare.org Less <<
NCT02399215 Carcinoid Tumor ... More >> Metastatic Carcinoid Tumor Neuroendocrine Neoplasm Less << Phase 2 Active, not recruiting August 1, 2019 United States, New York ... More >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 Less <<
NCT03513484 Acute Myeloid Leukemia With t(... More >>9;11)(p22.3;q23.3); MLLT3-KMT2A Fibroblast Growth Factor Basic Form Measurement FLT3 Internal Tandem Duplication Recurrent Adult Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Less << Phase 1 Recruiting January 2021 United States, Illinois ... More >> Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Jessica K. Altman ?? 312-695-6180 ?? j-altman@northwestern.edu ?? Principal Investigator: Jessica K. Altman Less <<
NCT02730416 Endometrial Cancer Phase 2 Recruiting July 2022 Denmark ... More >> NSGO Recruiting Copenhagen, Sjaelland, Denmark, 2100 Contact: Mette Berensen, RN ?? ?? mette.berensen.02@regionh.dk Less <<
NCT02531737 Lung Neoplasms Phase 2 Recruiting January 2019 France ... More >> CH de Beauvais Recruiting Beauvais, France Contact: Jacky Crequet, MD ?? 33.3 44 11 22 23 ?? Jacky.crequit@wanadoo.fr ?? Sub-Investigator: Jacky crequet, MD ?? ?? ?? Ch de Beauvais Recruiting Beauvais, France Principal Investigator: Jacky CREQUIT, MD ?? ?? ?? CHU Brest Recruiting Brest, France Contact: G. ROBINET, MD ?? ?? ?? Principal Investigator: G ROBINET, MD ?? ?? ?? Service de Pneumologie Recruiting Créteil, France Contact: Isabelle Monnet, MD ?? 33.1 45 17 50 14 ?? Isabelle.Monnet@chicreteil.fr ?? Principal Investigator: Isabelle Monnet, MD ?? ?? ?? Service de Pneumologie Recruiting Gap, France Contact: P Thomas, MD ?? 33.4 92 40 61 26 ?? pneumologie@ch-gap.fr ?? Principal Investigator: P Thomas, MD ?? ?? ?? CHU de Limoges Recruiting Limoges, France, 87000 Contact: A. Vergnenegre, MD ?? ?? alain.vergnenegre@unilim.fr ?? Principal Investigator: B. Melloni, MD ?? ?? ?? Principal Investigator: A. Vergnenegre, MD ?? ?? ?? CH de Bretagne Sud Recruiting LOrient, France Contact: Regine LAMY, MD ?? ?? ?? Principal Investigator: Regine LAMY, MD ?? ?? ?? Centre Hospitalier F. Quesnay Recruiting Mantes La Jolie, France, 78200 Contact: JB. Auliac, MD ?? 33 (0)1 34 97 40 70 ?? j-b.auliac@ch-mantes-la-jolie.rss.fr ?? Principal Investigator: JB. Auliac, MD ?? ?? ?? AP-HM Recruiting Marseille, France Principal Investigator: Fabrice BARLESI, MD ?? ?? ?? Institut Paoli-Calmettes Recruiting Marseille, France Contact: Anne MADROSZYK, MD ?? ?? ?? Principal Investigator: Anne MADROSZYK, MD ?? ?? ?? Instiut de Cancérologie Recruiting Saint Etienne, France Principal Investigator: Pierre FOURNEL, MD ?? ?? ?? Service de Pneumologie Recruiting Villefranche, France Contact: L falchero, MD ?? 33.4 74 09 27 23 ?? lfalchero@ch-villefranche.fr ?? Principal Investigator: L Falchero, MD Less <<
NCT02665143 Relapsed/Refractory Acute Myel... More >>oid Leukemia Less << Phase 1 Phase 2 Recruiting December 2019 United States, Connecticut ... More >> Yale University Recruiting New Haven, Connecticut, United States, 06520 Contact: Rebecca Lilian ?? 203-737-8358 ?? rebecca.lilian@yale.edu ?? United States, Tennessee Vanderbilt Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Channing V Dudley, RN, MSN ?? 615-875-5503 ?? channing.v.dudley@vanderbilt.edu ?? Principal Investigator: Stephen Strickland, MD Less <<
NCT03377023 Non Small Cell Lung Cancer ... More >> Lung Cancer, Nonsmall Cell Non Small Cell Lung Cancer Metastatic Less << Phase 1 Phase 2 Recruiting February 2021 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Germaine Gonzalez-Vazquez ?? 813-745-6636 ?? germaine.gonzalezvazquez@moffitt.org ?? Contact: Jhanelle E. Gray, M.D. ?? 813-745-6895 ?? jhanelle.gray@moffitt.org Less <<
NCT02149108 Colorectal Neoplasms Phase 3 Completed - -
NCT01658462 Breast Cancer Phase 2 Unknown December 2016 France ... More >> CHU Amiens- H?pital Sud Amiens, France, 80 054 H?pital Privé les Bonnettes Arras, France, 62000 Centre Pierre Curie Beuvry, France, 62660 CH Compiègne-Noyon Compiègne, France, 60200 Centre Léonard de Vinci Dechy, France, 59 187 Centre Oscar Lambret Lille, France, 59 020 Polyclinique de Limoges - site Chénieux Limoges, France, 87039 Institut Jean Godinot Reims, France, 51056 CMCO de la C?te d'Opale Saint Martin les Boulogne, France, 62280 H?pital Bretonneau Tours, France, 37044 Nouvelle Clinique des Dentellières Valenciennes, France, 59300 Centre Alexis Vautrin Vandoeuvre Les Nancy, France, 54 500 Less <<
NCT02149108 - Completed - -
NCT02572752 - Completed - -
NCT02572752 Healthy Phase 1 Completed - Germany ... More >> Boehringer Ingelheim Investigational Site Biberach, Germany Less <<
NCT01907100 Mesothelioma Phase 3 Completed - -
NCT02191865 Hepatic Insufficiency Phase 1 Completed - Germany ... More >> 1199.200.49001 Boehringer Ingelheim Investigational Site Kiel, Germany Less <<
NCT02619162 Breast Cancer Phase 1 Unknown April 2018 Spain ... More >> Hospital Universitario de Fuenlabrada Recruiting Fuenlabrada, Madrid, Spain, 28942 Contact: Miguel Angel Quintela, PhD ?? +34-91.732.80.00 ext 2930 ?? mquintela@cnio.es ?? Contact: Berta Nasarre ?? +34-91.600.65.84 ?? bnasarre@ext.cnio.es ?? Principal Investigator: Miguel Quintela, PhD ?? ?? ?? Sub-Investigator: Juan Victor Apala ?? ?? ?? Sub-Investigator: Juan Antonio Guerra ?? ?? ?? Sub-Investigator: Diego Malón ?? ?? ?? Sub-Investigator: Laura Rodríguez ?? ?? ?? Hospital de La Princesa Recruiting Madrid, Spain, 28006 Contact: Ramón Colomer ?? +34.91.5202276 ?? rcolomer@seom.org ?? Contact: Anabel Ballestero ?? +34.91.5202276 ?? ?? Principal Investigator: Ramón Colomer, PhD ?? ?? ?? MD Anderson Cancer Center Withdrawn Madrid, Spain, 28033 Clínica Quirón Recruiting Madrid, Spain, 28223 Contact: Miguel Quintela, PhD ?? 91.732.8000 ext 2930 ?? mquintela@cnio.es ?? Principal Investigator: Miguel Quintela, PhD Less <<
NCT02191865 - Completed - -
NCT00806819 Carcinoma, Non-Small-Cell Lung Phase 3 Completed - -
NCT00806819 - Completed - -
NCT02308553 Cutaneous Malignant Melanoma Phase 1 Phase 2 Recruiting June 2018 Germany ... More >> University Hospital Essen Recruiting Essen, NRW, Germany, 45147 Contact: Dirk Schadendorf, Prof. Dr. ?? +49-201- 723 ext 4342 ?? dirk.schadendorf@uk-essen.de ?? Principal Investigator: Dirk Schadendorf, Prof. Dr. ?? ?? ?? Elbeklinikum Buxtehude Recruiting Buxtehude, Germany, 21614 Contact: Peter Mohr, Dr. med. ?? ?? peter.mohr@elbekliniken.de ?? Principal Investigator: Peter Mohr, Dr. med. ?? ?? ?? SRH Wald-Klinikum Gera Not yet recruiting Gera, Germany, 07548 Contact: Martin Kaatz, PD Dr. ?? ?? martin.kaatz@wkg.srh.de ?? Principal Investigator: Martin Kaatz, PD Dr. ?? ?? ?? National Centre for Tumour Diseases (NCT) Recruiting Heidelberg, Germany, 69120 Contact: Jessica Hassel, Dr. med. ?? ?? jessica.hassel@med.uni-heidelberg.de ?? Principal Investigator: Jessica Hassel, Dr. med. ?? ?? ?? Universit?tsklinikum des Saarlandes Not yet recruiting Homburg, Germany, 66421 Contact: Claudia Pf?hler, PD Dr. ?? ?? claudia.pfoehler@uks.eu ?? Principal Investigator: Claudia Pf?hler, PD Dr. ?? ?? ?? Klinikum der Stadt Ludwigshafen am Rhein gGmbH Recruiting Ludwigshafen, Germany, 67063 Contact: Edgar Dippel, Prof. Dr. ?? ?? dippele@klilu.de ?? Principal Investigator: Edgar Dippel, Prof. Dr. ?? ?? ?? Universit?tsklinikum Schleswig-Holstein, Campus Lübeck Not yet recruiting Lübeck, Germany, 23538 Contact: Patrick Terheyden, PD Dr. ?? ?? patrick.terheyden@uksh.de ?? Principal Investigator: Patrick Terheyden, PD Dr. ?? ?? ?? University Hospital München Recruiting München, Germany, 80337 Contact: Carola Berking, Prof. Dr. ?? ?? carola.berking@med.uni-muenchen.de ?? Principal Investigator: Carola Berking, Prof. Dr. ?? ?? ?? Fachklinik Hornheide Recruiting Münster, Germany, 48157 Contact: Michael Fluck, Dr. med. ?? ?? michael.fluck@fachklinik-hornheide.de ?? Principal Investigator: Michael Fluck, Dr. med. Less <<
NCT02234596 Esophagogastric Adenocarcinoma Phase 2 Active, not recruiting September 2019 United States, New Jersey ... More >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States, 07748 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering Westchester Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, New York, United States, 10065 Memorial Sloan Kettering at Mercy Medical Center Rockville Centre, New York, United States Less <<
NCT02300298 - Completed - -
NCT02393755 Colon Adenocarcinoma ... More >> Rectal Adenocarcinoma Recurrent Colon Carcinoma Recurrent Rectal Carcinoma Stage IVA Colon Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Rectal Cancer Less << Phase 2 Active, not recruiting January 1, 2019 United States, California ... More >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Less <<
NCT01417156 Pulmonary Fibrosis Phase 2 Completed - Japan ... More >> Boehringer Ingelheim Investigational Site Himeji, Hyogo, Japan Boehringer Ingelheim Investigational Site Sakai, Osaka, Japan Boehringer Ingelheim Investigational Site Seto, Aichi, Japan Boehringer Ingelheim Investigational Site Yokohama, Kanagawa, Japan Less <<
NCT02866370 Ovarian Clear Cell Carcinoma ... More >> Endometrial Clear Cell Carcinoma Less << Phase 2 Recruiting March 2021 United Kingdom ... More >> Beatson West of Scotland Cancer Centre Recruiting Glasgow, Lanarkshire, United Kingdom, G12 0YN Contact: Ros Glasspool ?? ?? ?? Principal Investigator: Ros Glasspool ?? ?? ?? Sub-Investigator: Iain McNeish ?? ?? ?? Ninewells Hospital Recruiting Dundee, Tayside, United Kingdom Principal Investigator: Michelle Ferguson ?? ?? ?? Clatterbridge Cancer Centre Recruiting Liverpool, Wirral, United Kingdom Principal Investigator: Rosemary Lord ?? ?? ?? Belfast City Hospital (Northern Ireland Cancer Centre) Recruiting Belfast, United Kingdom Principal Investigator: Sarah McKenna ?? ?? ?? Bristol Heamatology and Cancer Centre Recruiting Bristol, United Kingdom Principal Investigator: Axel Walther ?? ?? ?? Velindre Hospital Recruiting Cardiff, United Kingdom Principal Investigator: Rachel Jones ?? ?? ?? Kent & Canterbury Hospital Recruiting Kent, United Kingdom Principal Investigator: Justin Waters ?? ?? ?? Queen Elizabeth Queen Mother Hospital Recruiting Kent, United Kingdom Principal Investigator: Justin Waters ?? ?? ?? William Harvey Hospital Recruiting Kent, United Kingdom Principal Investigator: Justin Waters ?? ?? ?? St James Hospital Recruiting Leeds, United Kingdom Principal Investigator: Geoff Hall ?? ?? ?? Guy's Hosital Recruiting London, United Kingdom Principal Investigator: Ana Montes ?? ?? ?? Royal Marsden Hospital Recruiting London, United Kingdom Principal Investigator: Susannah Bannerjee ?? ?? ?? St Bartholomew's Hospital Not yet recruiting London, United Kingdom Principal Investigator: Melanie Powell ?? ?? ?? University College London Hospital Not yet recruiting London, United Kingdom Principal Investigator: Jonathan Ledermann ?? ?? ?? The Christie Hospital Recruiting Manchester, United Kingdom Principal Investigator: Andrew Clamp ?? ?? ?? Great Western Hospital Recruiting Swindon, United Kingdom Principal Investigator: Omar Khan ?? ?? ?? Musgrove Park Hospital Recruiting Taunton, United Kingdom Principal Investigator: Clare Barlow Less <<
NCT00514683 Pulmonary Fibrosis Phase 2 Completed - -
NCT02300298 Carcinoma, Non-Small-Cell Lung Phase 1 Completed - Japan ... More >> 1199.90.81001 Boehringer Ingelheim Investigational Site Chiba , Kashiwa, Japan 1199.90.81003 Boehringer Ingelheim Investigational Site Kanagawa, Yokohama, Japan 1199.90.81007 Boehringer Ingelheim Investigational Site Osaka, Osakasayama, Japan 1199.90.81006 Boehringer Ingelheim Investigational Site Osaka, Osaka, Japan 1199.90.81004 Boehringer Ingelheim Investigational Site Shizuoka, Sunto-gun, Japan 1199.90.81002 Boehringer Ingelheim Investigational Site Tokyo, Chuo, Japan Less <<
NCT01417156 - Completed - -
NCT02579603 - Completed - -
NCT02667704 Healthy Phase 1 Completed - Germany ... More >> Boehringer Ingelheim Investigational Site Biberach, Germany Less <<
NCT02667704 - Completed - -
NCT00514683 - Completed - -
NCT01225887 Endometrial Adenocarcinoma ... More >> Endometrial Clear Cell Adenocarcinoma Endometrial Mucinous Adenocarcinoma Endometrial Serous Adenocarcinoma Endometrial Squamous Cell Carcinoma Endometrial Transitional Cell Carcinoma Endometrial Undifferentiated Carcinoma Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm Recurrent Uterine Corpus Carcinoma Less << Phase 2 Completed - -
NCT02579603 Idiopathic Pulmonary Fibrosis Phase 4 Completed - United States, Connecticut ... More >> Western CT Medical Group, P.C. Danbury, Connecticut, United States, 06810 United States, Louisiana Tulane University Hospital and Clinic New Orleans, Louisiana, United States, 70112 United States, Minnesota Minnesota Lung Center Minneapolis, Minnesota, United States, 55407 United States, Missouri The Lung Research Center, LLC Chesterfield, Missouri, United States, 63017 United States, South Carolina Lowcountry Lung and Crit Care Charleston, South Carolina, United States, 29406 United States, Tennessee Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232-5735 Canada, British Columbia St. Paul's Hospital Vancouver, British Columbia, Canada, V6Z 1Y6 Canada, Manitoba Concordia Hospital Winnipeg, Manitoba, Canada, R2K 3S8 France HOP Avicenne Bobigny, France, 93009 HOP de la Cavale Blanche Brest, France, 29609 HOP Louis Pradel Bron cedex, France, 69677 HOP Calmette Lille, France, 59037 HOP Pasteur Nice, France, 06001 HOP Bichat Paris, France, 75018 HOP Pontchaillou Rennes, France, 35033 Germany Klinik Donaustauf Donaustauf, Germany, 93093 Ruhrlandklinik, Westdeutsches Lungenzentrum am Universit?tsklinikum Essen gGmbH Essen, Germany, 45239 Thoraxklinik-Heidelberg gGmbH am Universit?tsklinikum Heidelberg Heidelberg, Germany, 69126 Italy A.O.U. Policlinico Vittorio Emanuele Catania, Italy, 95124 Osp. S. Giuseppe Fatebenefratelli Milano, Italy, 20123 A.O.U. Senese Policlinico Santa Maria alle Scotte Siena, Italy, 53100 Netherlands Sint Antonius Ziekenhuis Nieuwegein, Netherlands, 3435 CM Erasmus Medisch Centrum Rotterdam, Netherlands, 3015 CE Less <<
NCT02009579 Uterine Cervical Neoplasms Phase 2 Recruiting July 2020 Belgium ... More >> CHU Saint-Pierre Active, not recruiting Bruxelles, Belgium Institut Jules Bordet Recruiting Bruxelles, Belgium Grand Hopital de Charleroi Active, not recruiting Charleroi, Belgium UZ Antwerpen Active, not recruiting Edegem, Belgium AZ Groeninge Recruiting Kortrijk, Belgium UZ Leuven Recruiting Leuven, Belgium, 3000 Principal Investigator: Ignace Vergote, MD ?? ?? ?? CHR Citadelle Recruiting Liege, Belgium CHU de Liège Recruiting Liège, Belgium, 4000 Contact: Christine Gennigens, MD ?? ?? ?? Clinique et maternite St. Elisabeth Recruiting Namur, Belgium Cliniques Universitaires mont godinne Active, not recruiting Yvoir, Belgium Germany Charité Med Uni Berlin Recruiting Berlin, Germany Contact: Radoslav Chekerov, MD ?? ?? ?? Universit?tsklinikum Carl Gustav Carus Dresden Recruiting Dresden, Germany Contact: Pauline Wimberger, MD ?? ?? ?? Kliniken Essen Mitte Active, not recruiting Essen, Germany Georg-August University G?ttingen Active, not recruiting Gottingen, Germany Medical University Greifswald Recruiting Greifswald, Germany Contact: Alexander Mustea, MD ?? ?? ?? University Tübingen Recruiting Tubingen, Germany Contact: Andreas Hartkopf, MD ?? ?? ?? Italy Centro Riferimento Oncologico Not yet recruiting Aviano, Italy Contact: Roberto Sorio, MD ?? ?? ?? Spedali Civili Not yet recruiting Brescia, Italy Contact: Germana Tognon, MD ?? ?? ?? Azienda Ospedaliera Cannizzaro Not yet recruiting Catania, Italy Contact: Paolo Scollo, MD ?? ?? ?? National Cancer Institute Recruiting Milano, Italy Contact: Ketta Lorusso, MD ?? ?? ?? Istituto Nazionale Tumori-Pascale Naples Active, not recruiting Naples, Italy Padova Istituti Oncologico Veneto Not yet recruiting Padova, Italy Contact: Maria Nicoletto, MD ?? ?? ?? University Pisa Not yet recruiting Pisa, Italy Contact: Angiolo Gadducci, MD ?? ?? ?? AUSL Reggio Emilia Not yet recruiting Reggio Emilia, Italy Contact: allesandra bologna, MD ?? ?? ?? Poloclinico A Gemelli Not yet recruiting Rome, Italy Contact: Giovanni Scambia, MD ?? ?? ?? Mauriziano -Torino Active, not recruiting Torino, Italy S. Anna Torino Recruiting Torino, Italy Contact: Paolo Zola, MD ?? ?? ?? Spain Hospital Provincial Reina Sofia Recruiting Córdoba, Spain, 14004 Contact: Maria Jesús Rubio, MD ?? ?? ?? H. Ramón y Cajal Recruiting Madrid, Spain, 28034 Contact: Eva Maria Guerra, MD ?? ?? ?? Hospital Clinico San Carlos Recruiting Madrid, Spain, 28040 Contact: Antonio Casado, MD ?? ?? ?? Hospital Universitario Morales Meseguer Recruiting Murcia, Spain, 30008 Contact: Helena Garcia, MD ?? ?? ?? Hospital Son Llatzer Recruiting Palma Mallorca, Spain, 07198 Contact: Isabel Bover, MD Less <<
NCT03062943 Lymphangioleiomyomatosis Phase 2 Recruiting October 2020 Italy ... More >> Pneumology unit Recruiting Milan, Italy, 20123 Contact: Sergio A Harari, MD ?? +39 02 55 40 4580 ?? sergioalfonso.harari@multimedica.it ?? Contact: Mara Cattaeno ?? +39 02 55 40 4127 ?? mara.cattaneo@multimedica.it ?? Principal Investigator: Sergio A Harari, MD ?? ?? ?? Sub-Investigator: Olga Torre, MD ?? ?? ?? Sub-Investigator: Roberto Cassandro, MD Less <<
NCT00706628 Prostatic Neoplasms Phase 2 Completed - United Kingdom ... More >> 1239.3.4402 Boehringer Ingelheim Investigational Site Belfast, United Kingdom 1239.3.4406 Boehringer Ingelheim Investigational Site Bournemouth, United Kingdom 1239.3.4408 Boehringer Ingelheim Investigational Site Brighton, United Kingdom 1239.3.4409 Boehringer Ingelheim Investigational Site Cheltenham, United Kingdom 1239.3.4405 Boehringer Ingelheim Investigational Site Glasgow, United Kingdom 1239.3.4403 Boehringer Ingelheim Investigational Site Newcastle Upon Tyne, United Kingdom 1239.3.4411 Boehringer Ingelheim Investigational Site Southampton, United Kingdom 1239.3.4401 Boehringer Ingelheim Investigational Site Sutton, United Kingdom 1239.3.4410 Boehringer Ingelheim Investigational Site Truro, United Kingdom Less <<
NCT00706628 - Completed - -
NCT00987935 Carcinoma, Hepatocellular Phase 2 Completed - Korea, Republic of ... More >> 1199.39.82001 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82002 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82003 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82004 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82005 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1199.39.82006 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of Taiwan 1199.39.88606 Boehringer Ingelheim Investigational Site Changhua, Taiwan 1199.39.88609 Boehringer Ingelheim Investigational Site Kaohsiung, Taiwan 1199.39.88610 Boehringer Ingelheim Investigational Site Kaohsiung, Taiwan 1199.39.88605 Boehringer Ingelheim Investigational Site Taichung, Taiwan 1199.39.88608 Boehringer Ingelheim Investigational Site Tainan City, Taiwan 1199.39.88602 Boehringer Ingelheim Investigational Site Tainan, Taiwan 1199.39.88601 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1199.39.88603 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1199.39.88604 Boehringer Ingelheim Investigational Site Taoyuan County, Taiwan 1199.39.88607 Boehringer Ingelheim Investigational Site Yunlin County, Taiwan Less <<
NCT00710762 - Completed - -
NCT02299141 Carcinoma, Non-Small-Cell Lung... More >> Non-Small Cell Lung Cancer Nonsmall Cell Lung Cancer Less << Phase 1 Recruiting February 28, 2020 United States, Missouri ... More >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Ramaswamy Govindan, M.D. ?? 314-362-5654 ?? rgovindan@wustl.edu ?? Contact: Cindy Fogal ?? 314-362-1518 ?? clfogal@wustl.edu ?? Principal Investigator: Ramaswamy Govindan, M.D. ?? ?? ?? Sub-Investigator: Saiama Waqar, M.D. ?? ?? ?? Sub-Investigator: Daniel Morgensztern, M.D. ?? ?? ?? Sub-Investigator: Ticiana Leal, M.D. ?? ?? ?? United States, Wisconsin University of Wisconsin Clinical Science Center Recruiting Madison, Wisconsin, United States, 53705 Contact: Ticiana Leal, M.D. ?? 608-265-1700 ?? tbleal@medicine.wisc.edu ?? Principal Investigator: Ticiana Leal, M.D. ?? ?? ?? Sub-Investigator: Toby C Campbell, M.D. ?? ?? ?? Sub-Investigator: Anne Traynor, M.D. ?? ?? ?? Sub-Investigator: Justine Yang Bruce, M.D. ?? ?? ?? Sub-Investigator: Rosemary Sahagian Neider, N.P. Less <<
NCT01225887 - Completed - -
NCT00710762 Ovarian Neoplasms Phase 2 Completed - United Kingdom ... More >> 1199.9.4413 Boehringer Ingelheim Investigational Site Burton on Trent, United Kingdom 1199.9.4412 Boehringer Ingelheim Investigational Site Cambridge, United Kingdom 1199.9.4407 Boehringer Ingelheim Investigational Site Creigiau, Cardiff, United Kingdom 1199.9.4410 St James's University Hospital Leeds, United Kingdom 1199.9.4401 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.9.4404 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.9.4409 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.9.4411 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.9.4406 Boehringer Ingelheim Investigational Site Manchester, United Kingdom 1199.9.4402 Boehringer Ingelheim Investigational Site Northwood, United Kingdom 1199.9.4405 Boehringer Ingelheim Investigational Site Sutton, United Kingdom Less <<
NCT00801294 Colorectal Neoplasms Phase 2 Completed - France ... More >> 1239.2.3305A clinique Saint Jean Lyon, France 1239.2.3305B Cabinet Médical Lyon, France 1239.2.3301A H?pital Saint Antoine Paris Cedex 12, France 1239.2.3301B H?pital Saint Antoine Paris Cedex 12, France 1239.2.3301C H?pital Saint Antoine Paris Cedex 12, France 1239.2.3301D H?pital Saint Antoine Paris Cedex 12, France 1239.2.3301E H?pital Saint Antoine Paris Cedex 12, France 1239.2.3301F H?pital Saint Antoine Paris Cedex 12, France 1239.2.3301G H?pital Saint Antoine Paris Cedex 12, France 1239.2.3301H H?pital Saint Antoine Paris Cedex 12, France 1239.2.3301I H?pital Saint Antoine Paris Cedex 12, France 1239.2.3301J H?pital Saint Antoine Paris Cedex 12, France 1239.2.3301K H?pital Saint Antoine Paris Cedex 12, France 1239.2.3302A H?pital Tenon Paris Cedex 20, France 1239.2.3302B H?pital Tenon Paris Cedex 20, France 1239.2.3304A H?pital Robert Debré Reims Cedex, France 1239.2.3304B H?pital Robert Debré Reims Cedex, France 1239.2.3304C H?pital Robert Debré Reims Cedex, France 1239.2.3303A Institut Gustave Roussy Villejuif Cedex, France 1239.2.3303B Institut Gustave Roussy Villejuif Cedex, France 1239.2.3303C Institut Gustave Roussy Villejuif Cedex, France 1239.2.3303D Institut Gustave Roussy Villejuif Cedex, France 1239.2.3303E Institut Gustave Roussy Villejuif Cedex, France 1239.2.3303F Institut Gustave Roussy Villejuif Cedex, France Less <<
NCT02808247 Sarcoma, Soft Tissue Phase 2 Recruiting January 2022 Belgium ... More >> Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet Recruiting Brussels, Belgium, 1000 Contact: Gil Thierry ?? +32 25413188 ?? thierry.gil@bordet.be ?? Cliniques Universitaires Saint-Luc (121) Recruiting Brussels, Belgium Contact: Filomena Mazzeo ?? ?? Filomena.Mazzeo@uclouvain.be ?? U.Z. Leuven - Campus Gasthuisberg (147) Recruiting Leuven, Belgium Contact: Patrick Sch?ffski ?? ?? patrick.schoffski@uzleuven.be ?? France Institut Bergonie Recruiting Bordeaux, France, 33076 Contact: Antoine Italiano ?? ?? a.italiano@bordeaux.unicancer.fr ?? Centre Leon Berard (227) Recruiting Lyon, France Contact: Jean-Yves Blay ?? ?? jean-yves.blay@lyon.unicancer.fr ?? Gustave Roussy (225) Recruiting Villejuif, France Contact: Olivier Mir ?? ?? olivier.mir@gustaveroussy.fr ?? Lithuania Vilnius University Hospital Santariskiu Santaros Clinics Klinikos (9453) Recruiting Vilnius, Lithuania, 08661 Netherlands The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis (301) Recruiting Amsterdam, Netherlands, 1066 Leiden University Medical Centre (310) Recruiting Leiden, Netherlands, 2300 Poland Maria Sklodowska-Curie Memorial Cancer Centre Recruiting Warsaw, Poland, 02 781 Contact: Piotr Rutkowski ?? ?? rutkowskip@coi.waw.pl ?? Spain Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia) Recruiting Barcelona, Spain, 08916 Contact: Anna Estival ?? ?? estivalanna@gmail.com ?? Hospital Universitario San Carlos (366) Recruiting Madrid, Spain, 28040 United Kingdom Royal Marsden Hospital - Chelsea, London (613) Recruiting London, United Kingdom, SW3 6JJ Less <<
NCT02225405 Stage IB Non-Small Cell Lung C... More >>arcinoma AJCC v7 Stage II Non-Small Cell Lung Cancer AJCC v7 Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7 Less << Phase 1 Active, not recruiting April 30, 2020 United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02568449 Recurrent Pleural Malignant Me... More >>sothelioma Stage IV Pleural Mesothelioma Less << Phase 2 Recruiting January 1, 2018 United States, California ... More >> University of California Davis Comprehensive Cancer Center Not yet recruiting Sacramento, California, United States, 95817 Contact: David R. Gandara ?? 916-734-8452 ?? david.gandara@ucdmc.ucdavis.edu ?? Principal Investigator: David R. Gandara ?? ?? ?? United States, Michigan University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Gregory P. Kalemkerian ?? 734-615-4762 ?? kalemker@umich.edu ?? Principal Investigator: Gregory P. Kalemkerian, M.D. ?? ?? ?? Wayne State University/Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Antoinette J. Wozniak ?? 313-576-8752 ?? wozniakt@karmanos.org ?? Principal Investigator: Antoinette J. Wozniak, M.D. ?? ?? ?? Sub-Investigator: Shirsh Gadgeel, M.D. ?? ?? ?? Sub-Investigator: Ammar Sukari, M.D. ?? ?? ?? United States, New York Memorial Sloan Kettering Cancer Center Not yet recruiting New York, New York, United States, 10065 Contact: Marjorie G. Zauderer, M.D. ?? 646-888-4201 ?? zauderem@mskcc.org ?? Principal Investigator: Marjorie G. Zauderer, M.D. Less <<
NCT01362361 Colorectal Cancer Phase 2 Unknown December 2013 Germany ... More >> Universit?tsklinikum Halle Recruiting Halle, Sachsen-Anhalt, Germany, 06120 Contact: Thomas Seufferlein, MD ?? ?? ?? Principal Investigator: Thomas Seufferlein, MD ?? ?? ?? Sub-Investigator: Thomas J. Ettrich, MD ?? ?? ?? Schwerpunktpraxis für H?matologie und Onkologie Bottrop und Dorsten Recruiting Bottrop, Germany Principal Investigator: Carla V. Hannig, MD ?? ?? ?? Universit?tsklinikum Greifswald -Klinik für Innere Medizin A Recruiting Greifswald, Germany Principal Investigator: Julia Mayerle, MD ?? ?? ?? Gemeinschaftspraxis und Tagesklinik Onkologie und Gastroenterologie - Halle Recruiting Halle, Germany Principal Investigator: Stefanie Frank-Gleich, MD ?? ?? ?? Klinikum Karlsruhe, Medizinische Klinik III Recruiting Karlsruhe, Germany Principal Investigator: Margarethe Schmier, MD ?? ?? ?? Kliniken der Stadt K?ln gGmbH - Krankenhaus Holweide Recruiting K?ln, Germany Principal Investigator: Claudia Lang, MD ?? ?? ?? Universit?tsmedizin Mannheim - TTZ am Interdisziplin?ren Tumorzentrum Recruiting Mannheim, Germany Principal Investigator: Ralf Hofheinz, MD ?? ?? ?? Joh. Wesling Klinikum Minden Recruiting Minden, Germany Principal Investigator: Hans-Joachim Tischler, MD ?? ?? ?? Stauferklinikum Schw?bisch Gmünd - Mutlangen - Zentrum Innere Medizin Recruiting Mutlangen, Germany Principal Investigator: Holger Hebart, MD ?? ?? ?? Klinikum der Universit?t München-Gro?hadern - Medizinische Klinik und Poliklink III Recruiting München, Germany Principal Investigator: Volker Heinemann, MD ?? ?? ?? Leopoldina-Krankenhaus Schweinfurt - Medizinische Klinik 2 Recruiting Schweinfurt, Germany Principal Investigator: Stephan Kanzler, MD ?? ?? ?? Universit?tsklinikum Ulm - Klinik für Innere Medizin I Recruiting Ulm, Germany Principal Investigator: G?tz von Wichert, MD Less <<
NCT01948141 Recurrent Non-small Cell Lung ... More >>Cancer Squamous Cell Lung Cancer Stage III Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Less << Phase 2 Completed - United States, New York ... More >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 United States, Ohio University Hospitals Case Medical Center Cleveland, Ohio, United States, 44106 Less <<
NCT00987935 - Completed - -
NCT00715403 Neoplasms Phase 1 Completed - France ... More >> 1199.16.3306A Boehringer Ingelheim Investigational Site Bordeaux cedex, France 1199.16.3311A Boehringer Ingelheim Investigational Site Clichy Cedex, France 1199.16.3311B Boehringer Ingelheim Investigational Site Clichy Cedex, France 1199.16.3313A Boehringer Ingelheim Investigational Site Paris Cedex 10, France 1199.16.3313E Boehringer Ingelheim Investigational Site Paris Cedex 10, France 1199.16.3302A Boehringer Ingelheim Investigational Site Paris cedex 15, France 1199.16.3312A Boehringer Ingelheim Investigational Site Paris, France Germany 1199.16.49001 Boehringer Ingelheim Investigational Site Freiburg/Breisgau, Germany 1199.16.49004 Boehringer Ingelheim Investigational Site Grosshansdorf, Germany 1199.16.49008 Boehringer Ingelheim Investigational Site Tübingen, Germany 1199.16.49005 Boehringer Ingelheim Investigational Site Wiesbaden, Germany Less <<
NCT01015118 Ovarian Neoplasms ... More >> Peritoneal Neoplasms Less << Phase 3 Completed - -
NCT02598193 - Completed - -
NCT01015118 - Completed - -
NCT01948141 - Completed - -
NCT01004003 Carcinoma, Hepatocellular Phase 2 Completed - Austria ... More >> 1199.37.43001 Boehringer Ingelheim Investigational Site Wien, Austria 1199.37.43002 Boehringer Ingelheim Investigational Site Wien, Austria France 1199.37.33001 Boehringer Ingelheim Investigational Site Paris, France 1199.37.33002 Boehringer Ingelheim Investigational Site Paris, France Germany 1199.37.49008 Boehringer Ingelheim Investigational Site Berlin, Germany 1199.37.49009 Boehringer Ingelheim Investigational Site Erlangen, Germany 1199.37.49002 Boehringer Ingelheim Investigational Site Freiburg, Germany 1199.37.49001 Boehringer Ingelheim Investigational Site Hannover, Germany 1199.37.49010 Boehringer Ingelheim Investigational Site Heidelberg, Germany 1199.37.49005 Boehringer Ingelheim Investigational Site Jena, Germany 1199.37.49004 Boehringer Ingelheim Investigational Site Magdeburg, Germany 1199.37.49003 Boehringer Ingelheim Investigational Site München, Germany 1199.37.49006 Boehringer Ingelheim Investigational Site Tübingen, Germany Hungary 1199.37.36001 Boehringer Ingelheim Investigational Site Debrecen, Hungary Netherlands 1199.37.31002 Boehringer Ingelheim Investigational Site Leiden, Netherlands 1199.37.31001 Boehringer Ingelheim Investigational Site Utrecht, Netherlands Poland 1199.37.48002 Boehringer Ingelheim Investigational Site Olsztyn, Poland 1199.37.48003 Boehringer Ingelheim Investigational Site Warsaw, Poland 1199.37.48001 Boehringer Ingelheim Investigational Site Warszawa, Poland Romania 1199.37.40002 Boehringer Ingelheim Investigational Site Bucharest, Romania 1199.37.40003 Boehringer Ingelheim Investigational Site Cluj-Napoca, Romania United Kingdom 1199.37.44001 Boehringer Ingelheim Investigational Site Edgbaston, Birmingham, United Kingdom 1199.37.44005 Boehringer Ingelheim Investigational Site Glasgow, United Kingdom 1199.37.44008 Boehringer Ingelheim Investigational Site Liverpool, United Kingdom 1199.37.44002 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.37.44003 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.37.44006 Boehringer Ingelheim Investigational Site Manchester, United Kingdom 1199.37.44004 Boehringer Ingelheim Investigational Site Nottingham, United Kingdom Less <<
NCT00715403 - Completed - -
NCT00904839 Colorectal Neoplasms Phase 2 Completed - -
NCT01004003 - Completed - -
NCT02598193 Idiopathic Pulmonary Fibrosis Phase 4 Completed - -
NCT01251484 Recurrent Glioblastoma Phase 2 Completed - Denmark ... More >> Rigshospitalet Copenhagen, Denmark, 2100 Less <<
NCT00904839 - Completed - -
NCT00730821 Neoplasms Phase 1 Completed - United States, Arizona ... More >> 1239.1.3 Boehringer Ingelheim Investigational Site Scottsdale, Arizona, United States United States, Florida 1239.1.1 Boehringer Ingelheim Investigational Site Tampa, Florida, United States United States, Michigan 1239.1.2 Boehringer Ingelheim Investigational Site Detroit, Michigan, United States United States, Nebraska 1239.1.4 Boehringer Ingelheim Investigational Site Omaha, Nebraska, United States Less <<
NCT02902484 Cancer of Pancreas Phase 1 Phase 2 Recruiting September 2020 United States, Texas ... More >> University of Texas Southwestern Medical Center Recruiting Dallas, Texas, United States, 75063 Contact: Silvia Pilarski, RN ?? 214-648-5919 ?? Silvia.Pilarski@UTSouthwestern.edu ?? Principal Investigator: Muhammad Beg, MD Less <<
NCT01484080 Breast Cancer Phase 1 Phase 2 Completed - Spain ... More >> Hospital Universitari de Bellvitge Hospitalet de Llobregat, Barcelona, Spain, 08907 Hospital Universitario de Fuenlabrada Fuenlabrada, Madrid, Spain, 28942 MD Anderson Cancer Centre Madrid Madrid, Spain, 28033 Less <<
NCT02182258 Healthy Phase 1 Completed - -
NCT02182193 Healthy Phase 1 Completed - -
NCT01136174 - Completed - -
NCT02182050 Carcinoma, Non-Small-Cell Lung Phase 2 Completed - -
NCT01170065 Pulmonary Fibrosis Phase 2 Completed - -
NCT00979576 Carcinoma, Non-Small-Cell Lung Phase 1 Terminated - Japan ... More >> 1199.28.003 Boehringer Ingelheim Investigational Site Chiba,Kashiwa, Japan 1199.28.002 Boehringer Ingelheim Investigational Site Miyakojima-ku, Osaka, Japan 1199.28.001 Boehringer Ingelheim Investigational Site Osaka-Sayama, Osaka, Japan Less <<
NCT01788982 Medullary Thyroid Cancer (MTC)... More >> Differentiated Thyroid Cancer (DTC) Less << Phase 2 Active, not recruiting December 2018 Belgium ... More >> A.Z. St. Jan Brugge, Belgium, 8000 Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet Brussels, Belgium, 1000 Cliniques Universitaires Saint-Luc Brussels, Belgium, 1200 Universitair Ziekenhuis Antwerpen Edegem, Antwerpen, Belgium, 2650 Universitair Ziekenhuis Gent Gent, Belgium, 9000 U.Z. Leuven - Campus Gasthuisberg Leuven, Belgium, 3000 Denmark Odense University Hospital Odense, Denmark, 5000 France CHU d'Angers Angers, France, 49933 Institut Bergonie Bordeaux, France, 33076 Centre Regional Francois Baclesse Caen, France, 14076 Centre Georges-Francois-Leclerc Dijon, France, 21079 Centre Leon Berard Lyon, France, 69008 Assitance Publique - Hopitaux de Paris - Hopital Saint-Louis Paris, France, 75475 Assistance Publique - Hopitaux de Paris - La Pitié Salpétrière Paris, France, 75651 Centre Jean Godinot Reims, France, 51056 Institut Gustave Roussy Villejuif, France Germany Ludwig-Maximilians-Universitaet Muenchen - Klinikum der Universitaet Muenchen - Campus Grosshadern Munich, Germany, DE 81377 Universitaetsklinikum Wuerzburg Wuerzburg, Germany, DE 97080 Italy Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Italy Azienda Ospedaliera Universitaria "Federico II" Napoli, Italy, 80131 Netherlands University Medical Center Groningen Groningen, Netherlands, 9713 Leiden University Medical Centre Leiden, Netherlands, 2300 Radboud University Medical Center Nijmegen Nijmegen, Netherlands, 6500 Poland Maria Sklodowska-Curie Memorial Cancer Centre Warsaw, Poland, PL 02 781 Spain Hospital General Vall D'Hebron Barcelona, Spain, ES 08035 United Kingdom Royal Marsden Hospital - Sutton, Surrey Sutton, Surrey, United Kingdom, SM2 5PT NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital Glasgow, United Kingdom, G12 0YN Less <<
NCT00979576 - Terminated - -
NCT01488344 Acute Myeloid Leukemia Phase 1 Phase 2 Unknown - Germany ... More >> Universit?tsklinikum Münster, Medizinische Klinik und Poliklinik A Münster, Germany, 48149 Less <<
NCT03283007 Lung-transplant Recipients Phase 3 Not yet recruiting May 2022 -
NCT03562416 Idiopathic Pulmonary Fibrosis ... More >> Lung Transplant; Complications Less << Phase 2 Not yet recruiting December 2021 United States, Pennsylvania ... More >> Temple University Hospital Not yet recruiting Philadelphia, Pennsylvania, United States, 19140 Contact: Francine McGonagle, BSN,RN ?? 215-707-2682 ?? Francine.McGonagle@tuhs.temple.edu ?? Contact: Shubhra Srivastava-Malhotra ?? 215-707-0945 ?? Shubhra.Srivastava-Malhotra@tuhs.temple.edu ?? Principal Investigator: Jonathan A Galli, MD ?? ?? ?? Sub-Investigator: Gerard J Criner, MD ?? ?? ?? Sub-Investigator: Patrick Mulhall, MD ?? ?? ?? Sub-Investigator: Kartik Shenoy, MD ?? ?? ?? Sub-Investigator: James Brown, MD ?? ?? ?? Sub-Investigator: Thomas Rogers, PhD Less <<
NCT02182154 Healthy Phase 1 Completed - -
NCT00805194 Carcinoma, Non-Small-Cell Lung Phase 3 Completed - -
NCT01022853 Neoplasms Phase 1 Completed - Italy ... More >> 1230.7.39002 Boehringer Ingelheim Investigational Site Ancona, Italy 1230.7.39001 Boehringer Ingelheim Investigational Site Milano, Italy Less <<
NCT00805194 - Completed - -
NCT02182245 Genital Neoplasms, Female Phase 1 Completed - -
NCT00876460 Carcinoma, Non-Small-Cell Lung Phase 1 Completed - Japan ... More >> 1199.29.002 Boehringer Ingelheim Investigational Site Fukuoka, Fukuoka, Japan 1199.29.001 Boehringer Ingelheim Investigational Site Osaka-Sayamashi, Osaka, Japan Less <<
NCT02182063 Prostatic Neoplasms Phase 2 Completed - -
NCT01024920 Carcinoma, Renal Cell Phase 2 Active, not recruiting February 15, 2019 Hungary ... More >> University of Pecs Medical School, Dept. of Oncotherapy Pecs, Hungary, 7624 Poland Ziemia Lubelska Oncological Center, Lublin Lublin, Poland, 20-099 Onco.Cent. - Instit. of Maria Sklodowskiej-Curie Warszawa, Poland, 02-781 Romania Military Central Clinical Emergency Hospital Bucharest, Romania, 010825 Sf. Nectarie Oncology Center, Craiova Craiova, Romania, 200347 ONCOLAB SRL, Craiova Craiova, Romania, 200385 Ukraine Municipal Establishment Cherkasy Oncology Centre Cherkasy, Ukraine, 18009 Bukovynsk State Medical University Chernivtsi, Ukraine, 58013 City Clinical Hospital #4, Dnipropetrovsk State Medical Academy Dnipropetrovks, Ukraine, 49102 CI of LRC Lviv Onco.Reg.Treat.&Diag.Cent. Lviv, Ukraine, 79031 Uzhgorod National University, Oncology Centre Uzhgorod, Ukraine, 88000 United Kingdom Addenbrooke's Hospital Cambridge, United Kingdom, CB2 0QQ Beatson West of Scotland Cancer Centre Glasgow, United Kingdom, G12 0YN Surrey Cancer Research Institute Guildford, United Kingdom, GU2 7WG St James's University Hospital Leeds, United Kingdom, LS9 7TF Less <<
NCT01380782 Glioblastoma ... More >>Gliosarcoma Anaplastic Astrocytoma Anaplastic Oligodendroglioma Anaplastic Oligoastrocytoma Less << Phase 2 Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Ohio Cleveland Clinic Cleveland, Ohio, United States, 44195 United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22908-4324 Less <<
NCT01022853 - Completed - -
NCT01335464 Pulmonary Fibrosis Phase 3 Completed - -
NCT02835833 Renal Cell Carcinoma ... More >> Colorectal Adenocarcinoma Non-squamous Non-small Cell Lung Cancer Platinum-refractory Ovarian Carcinoma Cervical Carcinoma Less << Phase 1 Completed - United States, Alabama ... More >> University of Alabama at Birmingham Comprehensive Cancer Center Birmingham, Alabama, United States, 35294 Less <<
NCT01136174 Idiopathic Pulmonary Fibrosis Phase 2 Completed - Japan ... More >> 1199.31.002 Boehringer Ingelheim Investigational Site Bunkyo-ku,Tokyo, Japan 1199.31.004 Boehringer Ingelheim Investigational Site Hamamatsu, Shizuoka, Japan 1199.31.008 Boehringer Ingelheim Investigational Site Himeji, Hyogo, Japan 1199.31.006 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1199.31.007 Boehringer Ingelheim Investigational Site Sakai, Osaka, Japan 1199.31.005 Boehringer Ingelheim Investigational Site Seto, Aichi, Japan 1199.31.001 Boehringer Ingelheim Investigational Site Shimotsuke,Tochigi, Japan 1199.31.003 Boehringer Ingelheim Investigational Site Yokohama, Kanagawa, Japan Less <<
NCT01380782 - Completed - -
NCT00998296 Neoplasms Phase 1 Completed - France ... More >> 1239.14.3301A Boehringer Ingelheim Investigational Site Villejuif Cedex, France Less <<
NCT00876460 - Completed - -
NCT01335477 - Completed - -
NCT01314105 Ovarian Neoplasms ... More >> Peritoneal Neoplasms Less << Phase 1 Completed - Spain ... More >> 1199.119.34001 Boehringer Ingelheim Investigational Site Barcelona, Spain 1199.119.34002 Boehringer Ingelheim Investigational Site Barcelona, Spain 1199.119.34003 Boehringer Ingelheim Investigational Site L'Hospitalet de Llobregat, Spain Less <<
NCT01441297 Small Cell Lung Cancer ... More >> Small Cell Lung Cancer Recurrent Less << Phase 2 Completed - Korea, Republic of ... More >> National Cancer Center Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769 Less <<
NCT01335477 Pulmonary Fibrosis Phase 3 Completed - -
NCT00998296 - Completed - -
NCT02182232 Carcinoma, Non-Small-Cell Lung Phase 1 Completed - -
NCT01683682 Carcinoma, Non-Small-Cell Lung Phase 1 Completed - Germany ... More >> Krankenhaus Gro?hansdorf Gro?hansdorf, Germany, D-22927 Klinikum Kassel GmbH Kassel, Germany, D-34125 Less <<
NCT01329549 Ovarian Neoplasms Phase 1 Terminated - Japan ... More >> 1199.117.003 Boehringer Ingelheim Investigational Site Akashi, Hyogo, Japan 1199.117.002 Boehringer Ingelheim Investigational Site Chuo-ku,Tokyo, Japan 1199.117.001 Boehringer Ingelheim Investigational Site Hidaka, Saitama, Japan Less <<
NCT01666600 Glioblastoma Multiforme Phase 1 Phase 2 Terminated(Interim Analysis fo... More >>r Feasibility) Less << - Germany ... More >> University Hospital Heidelberg, Department of Neurooncology Heidelberg, Baden-Württemberg, Germany, 69120 University Hospital Heidelberg, Department of Pharmacology Heidelberg, Baden-Württemberg, Germany, 69120 Less <<
NCT01314105 - Completed - -
NCT01346540 Carcinoma, Non-Small-Cell Lung Phase 1 Completed - Italy ... More >> 1199.82.39004 Boehringer Ingelheim Investigational Site Milano, Italy Netherlands 1199.82.3102 Boehringer Ingelheim Investigational Site Maastricht, Netherlands Spain 1199.82.3401 Boehringer Ingelheim Investigational Site Barcelona, Spain 1199.82.3406 Boehringer Ingelheim Investigational Site Madrid, Spain 1199.82.3410 Boehringer Ingelheim Investigational Site Málaga, Spain United Kingdom 1199.82.4401 Boehringer Ingelheim Investigational Site London, United Kingdom 1199.82.4402 Boehringer Ingelheim Investigational Site Manchester, United Kingdom Less <<
NCT02558387 Recurrent or Metastatic Saliva... More >>ry Gland Cancer of the Head and Neck Less << Phase 2 Unknown January 2017 Korea, Republic of ... More >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 Less <<
NCT01329549 - Terminated - -
NCT01335464 - Completed - -
NCT01684111 Carcinoma, Non-Small-Cell Lung Phase 1 Completed - Germany ... More >> Klinikum Kassel GmbH Kassel, Hessen, Germany, 34125 LungenClinic Gro?hansdorf GmbH Gro?hansdorf, Germany, 22927 Thoraxklinik Universit?tsklinikum Heidelberg Heidelberg, Germany, D-69126 Klinikum der Universit?t München München, Germany, D-80336 Less <<
NCT02182141 Multiple Myeloma Phase 1 Completed - -
NCT01610869 Ovarian Cancer ... More >> Fallopian Tube Cancer Less << Phase 2 Active, not recruiting January 2019 United Kingdom ... More >> Kent Oncology Centre Maidstone, Kent, United Kingdom Beatson West of Scotland Cancer Centre Glasgow, Scotland, United Kingdom Velindre Hospital Cardiff, Wales, United Kingdom Royal United Hospital Bath, United Kingdom Addenbrookes Hospital Cambridge, United Kingdom Royal Derby Hospital Derby, United Kingdom Royal Surrey County Hospital Guildford, United Kingdom St James's University Hospital Leeds, United Kingdom Clatterbridge Centre for Oncology Liverpool, United Kingdom Mount Vernon Hospital London, United Kingdom Royal Marsden Hospital London, United Kingdom St Bartholomew's Hospital London, United Kingdom University College London Hospital (UCLH) London, United Kingdom Christie Hospital Manchester, United Kingdom Churchill Hospital Oxford, United Kingdom Wexham Park Hospital Slough, United Kingdom Less <<
NCT02496585 Lung Cancer L... More >>ung Metastases Less << Phase 2 Recruiting July 2019 United States, Massachusetts ... More >> Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Raymond Mak, MD ?? 617-632-3591 ?? ?? United States, New Jersey Memorial Sloan Kettering Cancer Center at Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Andreas Rimner, MD ?? 212-639-6025 ?? ?? Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Andreas Rimner, MD ?? 212-639-6025 ?? ?? Memorial Sloan Kettering Bergen Recruiting Montvale, New Jersey, United States, 07645 Contact: Andreas Rimner, MD ?? 212-639-6025 ?? ?? United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Recruiting Commack, New York, United States, 11725 Contact: Andreas Rimner, MD ?? 212-639-6025 ?? ?? Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Andreas Rimner, MD ?? 212-639-6025 ?? ?? Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Andreas Rimner, MD ?? 212-639-6025 ?? ?? Contact: Jamie Chaft, MD ?? 646-888-4545 ?? ?? Principal Investigator: Andreas Rimner, MD ?? ?? ?? Memorial Sloan Kettering at Mercy Medical Center Recruiting Rockville Centre, New York, United States Contact: Andreas Rimner, MD ?? 212-639-6025 ?? ?? Contact: Jamie Chaft, MD ?? 646-888-4545 ?? ?? Principal Investigator: Andreas Rimner, MD ?? ?? ?? United States, Texas Md Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Daniel Gomez, MD ?? 713-563-8446 ?? ?? Principal Investigator: Daniel Gomez, MD Less <<
NCT01346540 - Completed - -
NCT01619085 Idiopathic Pulmonary Fibrosis Phase 3 Active, not recruiting March 4, 2019 -
NCT02182219 Prostatic Neoplasms Phase 1 Completed - -
NCT02182102 Carcinoma, Non-Small-Cell Lung Phase 1 Completed - -
NCT01951846 Malignant Solid Tumour Phase 1 Completed - Germany ... More >> Klinik für Tumorbiologie, Abteilung Internistische Onkologie Freiburg, Germany, 79106 Less <<
NCT02152059 Small Cell Lung Cancer ... More >> Platinum-sensitive Less << Phase 2 Withdrawn(contract issues) - Canada, Alberta ... More >> Cross Cancer Institute Edmonton, Alberta, Canada, T6G 1Z2 Less <<
NCT02278978 Urothelial Carcinoma Phase 2 Unknown March 2016 Taiwan ... More >> Chia-Chi Lin Taipei, Taiwan Less <<
NCT02182206 Tumors Phase 1 Completed - -
NCT01349296 Solid Tumors Phase 1 Completed - Germany ... More >> University Hospital of Cologne Cologne, NRW, Germany, 50937 Less <<
NCT01485874 Ovarian Cancer Phase 1 Terminated(Funding withdrawn d... More >>ue to drug unavailability) Less << - United States, Indiana ... More >> Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 Less <<
NCT01669798 Ovarian Cancer ... More >> Fallopian Tube Cancer Peritoneal Cancer Less << Phase 2 Completed - United States, North Carolina ... More >> Duke Cancer Institute Durham, North Carolina, United States, 27710 United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22908 Virginia Oncology Associates Norfolk, Virginia, United States, 23502 Less <<
NCT02182128 Tumors Phase 1 Completed - -
NCT01619085 - Active, not recruiting - -
NCT02389764 Breast Cancer Phase 2 Terminated(Slow Accrual) - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02182076 Healthy Phase 1 Completed - -
NCT01669798 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.85mL

0.37mL

0.19mL

9.27mL

1.85mL

0.93mL

18.53mL

3.71mL

1.85mL
Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records